Pharming Group N.V. announced that the U.S. Food and Drug Administration (FDA) has accepted for review Pharming's supplemental Biologics License Application (sBLA) for RUCONEST® for routine prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema (HAE). The FDA has indicated that the sBLA is sufficiently complete to permit a substantive review and has set an action date of September 21, 2018.